Market Overview:
The global D-dimer testing market is expected to exhibit a CAGR of 4.45% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
D-dimer testing refers to blood tests used for the diagnosis of deep vein thrombosis (DVT), pulmonary embolism, and disseminated intravascular coagulation (DIC). The tests are conducted to identify the presence of D-dimer in the blood and locate any chronic clots in the body. The tests involve the introduction of monoclonal anti-D-dimer bodies with latex particles that enhance the molecular weight of the immunocomplexes in the test sample. The resulting change in the sample's turbidity is captured photometrically by various turbidimetric analyzers. These tests are usually conducted in hospitals, diagnostic centers, and laboratories.
D-Dimer Market Trends:
The increasing prevalence of chronic medical ailments, such as atrial fibrillation, coronary artery disease, and acute pancreatitis, across the globe, is among the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, and the increasing health consciousness among the masses are providing a thrust to the market growth. Various technological advancements, such as the development of next-generation Point-of-Care (PoC) D-dimer testing solutions, are acting as other growth-inducing factors. These innovative solutions process the results faster with enhanced accuracy and minimize the waiting time, resulting in an improved patient experience. Moreover, diagnostic centers are also widely using aptamers that minimize the requirement of antibodies for D-dimer testing and are more cost-effective in nature, thereby creating a positive outlook for market growth. Other factors, including rising healthcare expenditure capacities of the consumers, along with extensive research and development (R&D) activities, are anticipated to drive the market toward growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global D-dimer testing market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on test type, product, method, application and end use.
Breakup by Test Type:
- Clinical Laboratory Tests
- Point-of-Care Tests
Breakup by Product:
- Analyzers
- Reagents and Consumables
Breakup by Method:
- Enzyme-linked Immunosorbent Assay (ELISA)
- Latex-enhanced Immunoturbidimetric Assays
- Fluorescence Immunoassays
- Others
Breakup by Application:
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Disseminated Intravascular Coagulation (DIC)
- Others
Breakup by End Use:
- Hospitals
- Academic and Research Institutes
- Diagnostic Centers
- Others
Breakup by Region:
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, BioMedica Diagnostics, biomérieux SA, Diazyme Laboratories Inc. (General Atomics), F. Hoffmann-La Roche Ltd., HORIBA Ltd., Quidel Corporation, Sekisui Diagnostics LLC (Sekisui Chemical Co. Ltd.), Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., Unbound Medicine Inc and Werfen.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2021 |
Historical Period |
2016-2021 |
Forecast Period |
2022-2027 |
Units |
US$ Million |
Segment Coverage |
Test Type, Product, Method, Application, End Use, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Abbott Laboratories, BioMedica Diagnostics, biomérieux SA, Diazyme Laboratories Inc. (General Atomics), F. Hoffmann-La Roche Ltd., HORIBA Ltd., Quidel Corporation, Sekisui Diagnostics LLC (Sekisui Chemical Co. Ltd.), Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., Unbound Medicine Inc and Werfen |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global D-dimer testing market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global D-dimer testing market?
- What are the key regional markets?
- What is the breakup of the market based on the test type?
- What is the breakup of the market based on the product?
- What is the breakup of the market based on the method?
- What is the breakup of the market based on the application?
- What is the breakup of the market based on the end use?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global D-dimer testing market and who are the key players?
- What is the degree of competition in the industry?